IBM Watson collaborates with Broad Institute to explore genomics data
Category: #health  By Pankaj Singh  Date: 2019-02-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

IBM Watson collaborates with Broad Institute to explore genomics data

The initiative is expected enhance understanding of intrinsic possibility that individuals have for any specific disease.

IBM Watson Health, a cognitive healthcare solution company recently announced multiple new partnership deals. One of them is a collaborative deal with the Broad Institute of MIT and Harvard.

The IBM division that is based in Cambridge, Massachusetts, has been reported to say that the extended collaboration with Broad Institute is aimed at exploring and analyzing genomics data for the enhanced understanding of intrinsic possibility that individuals have for any specific disease.

IBM Watson has been reported to say that through the newly formed initiative, the company will be working to incorporate hospital and population-based biobank data, electronic health records and genomic information to improve genetic risk scoring. The project also aims at making its tools and insights available to the research community. Such tools include means for genome variants-based calculation of an individual’s risk of developing common diseases.

Sekar Kathiresan, Director, Broad Institute cardiovascular disease initiative has been reported to say that the institute is looking forward to developing upon the advances it has made in the field of polygenic risk scoring with the vast amount of genomic data. He added that the addition of clinical data with genomic data creates an excellent opportunity to enhance polygenic risk scoring and makes it more robust and powerful, transforming patient care.

According to sources, the recent deal is an expansion on a five-year deal previously signed by the groups in 2016. The initial phase of the new project will be undertaken for three years.

John Kelly, Senior Vice President, IBM Watson Health, has been reported to say in an official press release that the company is working directly with physician-scientists of Broad Institute to enhance AI to help it unlock undiscovered clues in the human health. He said that IBM Watson Health has built a deep expertise in the application of AI for understanding the complexities and meaning of massive amounts of genomics and health records data. He added that the latest collaboration is expected to combine such capabilities with clinical insights and improve technology’s chances of providing explicable insights to clinicians in the study and treatment of serious health conditions.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...